A survey of physicians’ treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries

References

• Acharya SS. Advances in hemophilia and the role of current and emerging prophylaxis. Am J Manag Care. 2016;22(5 Suppl):s116–s125.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. What is hemophilia? [cited Aug 2020]. Available from: https://www.cdc.gov/ncbddd/hemophilia/facts.html
   Google Scholar
• White GC, 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on thrombosis and haemostasis. Thromb Haemost. 2001;85(3):560.
   PubMed Web of Science ®Google Scholar
• Mansouritorghabeh H. Clinical and laboratory approaches to hemophilia A. Iran J Med Sci. 2015;40(3):194–205.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1–158.
   PubMed Web of Science ®Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546.
   PubMed Web of Science ®Google Scholar
• Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317–325.
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014;12(11):1788–1800.
   PubMed Web of Science ®Google Scholar
• Bullement A, McMordie ST, Hatswell AJ, et al. Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia a in Italy incorporating real-world dosing and joint health data. Pharmacoecon Open. 2020;4(1):133–142.
   PubMed Web of Science ®Google Scholar
• Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia a and B. Haemophilia. 2018;24(3):414–419.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Boscarino M, et al. Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia. 2019;25(6):946–952.
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Matichecchia A, Rivolta GF, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-Centre real-world experience. Blood Transfus. 2019;18:374–385.
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13(6):967–977.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Wolfsegger M, Steinitz KN, et al. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis-new insight provided by pharmacokinetic modelling. Haemophilia. 2015;21(3):300–306.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Alprolix summary of product characteristics. [cited Mar 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Elocta Summary of Product Characteristics. [cited Mar 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_en.pdf.
   Google Scholar
• European Haemophilia Network (EUHANET). European guidelines for the certification of Haemophilia Centres. [cited Sep 2020]. Available from: http://www.euhanet.org/docs/euhanet-european_guidelines_for_the_certification_of_haemophilia_centres_2013.pdf.
   Google Scholar
• Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study. Haemophilia. 2020;26(3):494–502.
   PubMed Web of Science ®Google Scholar
• Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4(2):e75–e82.
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262–e271.
   PubMed Web of Science ®Google Scholar
• Powell J, Shapiro A, Ragni M, et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol. 2015;168(1):113–123.
   PubMed Web of Science ®Google Scholar
• Stephensen D, Drechsler WI, Scott OM. Outcome measures monitoring physical function in children with haemophilia: a systematic review. Haemophilia. 2014;20(3):306–321.
   PubMed Web of Science ®Google Scholar
• Lamb CC, Wolfberg A, Lyytinen K. UK vs US physician decision-making in the treatment of haemophilia. Haemophilia. 2019;25(4):616–625.
   PubMed Web of Science ®Google Scholar
• Khair K, Pollard D, Harrison C, et al. HOw patients view extended half-life products: Impressions from real-world experience (the HOPE study). Haemophilia. 2019;25(5):814–820.
   PubMed Web of Science ®Google Scholar
• Hermans C, Klamroth R, Richards M, et al. Outcome measures in European patients with haemophilia: survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB. Haemophilia. 2017;23(2):222–229.
   PubMed Web of Science ®Google Scholar
• Iorio A, Krishnan S, Myren KJ, et al. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. J Med Econ. 2017;20(4):337–344.
   PubMed Web of Science ®Google Scholar
• Keepanasseril A, Stoffman J, Bouskill V, et al. Switching to extended half-life products in Canada - preliminary data. Haemophilia. 2017;23(4):e365–e367.
   PubMed Web of Science ®Google Scholar
• van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: a qualitative Study. Patient. 2020;13(2):201–210.
   PubMedGoogle Scholar
• Steen Carlsson K, Andersson E, Berntorp E. Preference-based valuation of treatment attributes in haemophilia a using web survey. Haemophilia. 2017;23(6):894–903.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Hay CRM, Jiménez-Yuste V, et al. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study. BMJ Open. 2019;9(5):e028012.
   PubMed Web of Science ®Google Scholar
• Oldenberg J, Heller C, Malmström H, et al. No relapse in patients with previous inhibitors switched to rFVIIIFc in ongoing observational phase 4 studies. Res Pract Thromb Haemost. 2020;4:463–464.
   Google Scholar